It has been suggested that EZH2 enforces the silencing of E-cadherin in basal breast cancers and BRCA1-deficient tumors, and promotes the mesenchymal cell states of these carcinoma cells by driving H3K27me3 that is associated with the CDH1 promoter [14]. This evidence concerns the gene CDH1 and carcinoma.